P18. Quantitative multigene expression profiling of primary prostate cancer

Purpose: To study the diagnostic value of PET-CT with 68Ga-PSMA-11 in the diagnosis of a primary prostate cancer, preoperative staging, and the detection of recurrence of prostate cancer (PCa). Methods: 28 patients aged 64.7 ± 8.74 years were included. 10 patients primary prostate cancer, and 18 patients with biochemical recurrence of the disease after radical treatment were examined. All patients underwent PET-CT with 68Ga-PSMA-11 according the whole body protocol. Interpretation of images was performed visually and quantitatively by calculation of SUL max. Results: High focal or diffuse 68Ga-PSMA-11 uptake was found in prostate parenchyma in patients with primary prostate cancer. Additionally metastases in regional lymph nodes were diagnosed in 4 patients and bone metastases were found in one patient. The correlation between 68Ga-PSMA-11 uptake level and Gleason index in the primary tumor (R Spearmen = 0.25, p = 0.57) was not observed. PET-positive results were obtained in 14 patients and PET-negative results in 4 patients with biochemical recurrence of PCa. The relationship between the frequency of PET-positive results and Gleason index was not revealed (R Spearmen = 0.2, p = 0.39). We found a weak but significant correlation between the frequency of PET-positive results and the prostate tumor stage according to the T category (R Spearmen = 0.49, p = 0.049). In patients with low values of PSA (less than 1.0 ng/ml) in 4 out of 9 cases, PET-negative results were obtained. In patients with PSA level more than 1.0 ng/ml PET-positive results were obtained in all cases. Conclusions: PET/CT with 68Ga-PSMA-11 allows to diagnose the primary prostate cancer, to establish the stage of the disease in categories N and M, and also to determine the localization and dissemination of the tumor in patients with biochemical recurrence of prostate cancer. The relationship between 68Ga-PSMA-11 uptake in primary tumor and Gleason index was not found. The probability of obtaining PET-positive results in cases of biochemical recurrence is affected by a PSA level above 1 ng/ml and a high stage of the disease according to the T category (T3-T4).

Download Full-text

Imaging Primary Prostate Cancer and Bone Metastasis

10.21236/ada472718 ◽

2007 ◽

Author(s):

Xiaoyuan Chen

Keyword(s):

Prostate Cancer ◽

Bone Metastasis ◽

Primary Prostate Cancer

Download Full-text

Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer

European Urology ◽

10.1016/j.eururo.2021.03.017 ◽

2021 ◽

Author(s):

Carissa E. Chu ◽

Mohammed Alshalalfa ◽

Martin Sjöström ◽

Shuang G. Zhao ◽

Yang Liu ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Features ◽

Molecular Subtypes ◽

Prostate Specific Membrane Antigen ◽

Primary Prostate Cancer ◽

Specific Membrane

Download Full-text

Transcriptional landscape of PTEN loss in primary prostate cancer

BMC Cancer ◽

10.1186/s12885-021-08593-y ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Eddie Luidy Imada ◽

Diego Fernando Sanchez ◽

Wikum Dinalankara ◽

Thiago Vidotto ◽

Ericka M. Ebot ◽

...

Keyword(s):

Prostate Cancer ◽

Meta Analysis ◽

Pten Loss ◽

Primary Prostate Cancer ◽

Expression Atlas ◽

Transcriptomic Signature ◽

Transcriptional Changes ◽

New Biomarkers ◽

Adaptive Immune Systems ◽

Transcriptional Landscape

Abstract Background PTEN is the most frequently lost tumor suppressor in primary prostate cancer (PCa) and its loss is associated with aggressive disease. However, the transcriptional changes associated with PTEN loss in PCa have not been described in detail. In this study, we highlight the transcriptional changes associated with PTEN loss in PCa. Methods Using a meta-analysis approach, we leveraged two large PCa cohorts with experimentally validated PTEN and ERG status by Immunohistochemistry (IHC), to derive a transcriptomic signature of PTEN loss, while also accounting for potential confounders due to ERG rearrangements. This signature was expanded to lncRNAs using the TCGA quantifications from the FC-R2 expression atlas. Results The signatures indicate a strong activation of both innate and adaptive immune systems upon PTEN loss, as well as an expected activation of cell-cycle genes. Moreover, we made use of our recently developed FC-R2 expression atlas to expand this signature to include many non-coding RNAs recently annotated by the FANTOM consortium. Highlighting potential novel lncRNAs associated with PTEN loss and PCa progression. Conclusion We created a PCa specific signature of the transcriptional landscape of PTEN loss that comprises both the coding and an extensive non-coding counterpart, highlighting potential new players in PCa progression. We also show that contrary to what is observed in other cancers, PTEN loss in PCa leads to increased activation of the immune system. These findings can help the development of new biomarkers and help guide therapy choices.

Download Full-text